S-Alpha Therapeutics, Inc. To Present at Ophthalmology Innovation Summit During 2023 OIS@SECO in Atlanta, GA, USA

SAN FRANCISCO–(BUSINESS WIRE)–S-Alpha Therapeutics, Inc., a company developing new solutions for children with Myopia, announced today that Youngmin Huh, Ph.D., Data Science Leader, will present interim data from clinical trial using its novel, investigational device SAT-001 at Ophthalmology Innovation Summit held on 1^st of March 2023, at OIS@SECO, Atlanta, GA, USA.

SAT-001 is software as a medical device developed to improve pediatric myopia. SAT-001 employs a game interface that allows children to receive treatment while playing games on a daily basis. Initial clinical trial data from South Korea was used to design the current ongoing feasibility trial being conducted in the U.S.

There is a growing unmet need to develop treatments for pediatric myopia. The prevalence of myopia in Asian children is increasing rapidly. There is a clear and urgent need for safe and early intervention to slow the progression of myopia in children.

SAT-001 software allows non-contact intervention for slowing the progression of myopia. SAT-001 has games that children can enjoy daily. This game play engages the children in an activity which reduces the rate of axial elongation, the major cause of pediatric myopia.

Based on the interim data analysis from South Korean clinical trial, S-Alpha Therapeutics now plans to conduct a pivotal study in South Korea and has used this data to enhance its ongoing feasibility study in USA. The goal of the trial is to demonstrate that SAT-001 software can effectively slow the progression of myopia in children, while having fewer adverse events and providing enjoyable experience.

“We have made great strides in developing SAT-001. We believe that in the near future, SAT-001 can be a unique and enjoyable option to slow the progression of myopia in children, while also providing a positive experience,” states Dr. Yong-Sun Lee, CSO of S-Alpha Therapeutics, Inc and Officer of S-Alpha Therapeutics USA, Inc.

About SAT-001

SAT-001 is a proprietary software system designed to slow the progress of myopia, in form of game, which is performed about 30 minutes a day by children with myopia.

About S-Alpha Therapeutics, Inc.

Based in South Korea and USA, S-Alpha Therapeutics is a clinical trial stage company developing software systems and solutions for unmet medical needs.

Since its inception, S-Alpha Therapeutics, Inc. has completed exclusive worldwide patent registrations and applications for new applications for its software. Patent applications and registrations include pipelines with the potential to treat other diseases with unmet medical needs.

Contacts

Yong-Sun Lee, PhD

Chief Strategy Officer

[email protected]
Phone : 82-2-3487-3923